Rare Bleeding Disorders
Other Therapy Areas
Explore diabetes
Explore obesity
Explore growth-related disorders
Explore rare bleeding disorders
Explore rare renal disorders
Explore hormone replacement therapy
Medical Information | Non-US Health Care Professionals
Account Settings
Sign Out
Sign In | Create Account
  • Rare Bleeding Disorders Home
    • Products
      Our Treatments How to Order Trial Prescriptions Recombinant Manufacturing
    • Professional Resources
      Product Resources Library Contact Your Representative
    • Disease Education
      Clinical Education Library Congenital Hemophilia with Inhibitors Breakthrough Bleeds Acquired Hemophilia Glanzmann's Thrombasthenia Interactive Joint Bleed Model
    • Treatment Guidelines
      MASAC Guidelines WFH Guidelines
    • Additional Resources
      Organizations & Conferences
    • Product Education
      Product Education Materials
    • Disease Education
      Disease Education Resources
    • Access & Affordability
      Prescription Savings & Insurance Support ICD-10 Codes for Rare Bleeding Disorders
  • Sign In
    Create Account
    • Account Settings
    • Sign Out
    Other Therapy Areas
    Medical Information
    Non-US Health Care Professionals
NovoSeven® RT (coagulation Factor VIIa, recombinant) logo
Important Safety Information | Patient Site
Prescribing Information
    • Why NovoSeven® RT?
    • Pharmacology
    • Congenital Hemophilia A & B with Inhibitors
    • Breakthrough Bleeds
    • Acquired Hemophilia
    • Congenital Factor VII Deficiency
    • Glanzmann's Thrombasthenia
    • Hospital Overview
    • Clinical Pathway for Emergent Bleeds
    • Clinical Pathway for Acquired Hemophilia
    • Hospital Pharmacies
    • Dosing Calculator
    • Quick Reference
    • Administration
  • Cost & Coverage
    • Patient Education
    • Education for You
    • How to Order
NovoSeven® RT (coagulation Factor VIIa, recombinant) logo

Indicated for treatment of bleeding episodes and perioperative management in adults and children with hemophilia A or B with inhibitors, congenital factor VII (FVII) deficiency, Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, and in adults with acquired hemophilia.

Prescribing Information
Important Safety Information | Patient Site

Clinical Pathway for emergent bleeding in patients with congenital hemophilia.

Clinical Pathway for emergent bleeding in patients with congenital hemophilia.

Line map with multiple markers

This algorithm is meant to raise awareness of common steps for treating emergent bleeds in the emergency department (ED) setting.a Review the journey and patient case study that follows the same steps.

aThe provided example is for discussion purposes only and is not intended to represent a recommended algorithm for actual decision making. This example and the accompanying patient case study are for illustrative purposes and do not constitute guidance for medical advice or treatment.

This algorithm is meant to raise awareness of common steps for treating emergent bleeds in the emergency department (ED) setting.a Review the journey and patient case study that follows the same steps.

aThe provided example is for discussion purposes only and is not intended to represent a recommended algorithm for actual decision making. This example and the accompanying patient case study are for illustrative purposes and do not constitute guidance for medical advice or treatment.

Patient with knee pain

See the illustrative patient case study for congenital hemophilia. The case study provides an example of how NovoSeven® RT can be used to help patients who present with emergent bleeding.

See case study
See case study

Have questions about the clinical pathway or patient case study?

Chase CHAwI

Approved for bleed management and surgical use in congenital hemophilia with inhibitors.

See the clinical data
HCP working on computer

More recommendations for treating patients with hemophilia with inhibitors.

Go to MASAC recommendations

Selected Important Safety Information for NovoSeven® RT

WARNING: THROMBOSIS

  • Serious arterial and venous thrombotic events following administration of NovoSeven® RT have been reported
  • Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven® RT
  • Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis

Warnings and Precautions

  • Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance
  • Patients with congenital hemophilia receiving concomitant treatment with aPCCs (activated prothrombin complex concentrates), older patients particularly with acquired hemophilia and receiving other hemostatic agents, and patients with a history of cardiac and vascular disease may have an increased risk of developing thrombotic events

Indications and Usage

NovoSeven® RT (coagulation Factor VIIa, recombinant) is a coagulation factor indicated for:

  • Treatment of bleeding episodes and perioperative management in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets
  • Treatment of bleeding episodes and perioperative management in adults with acquired hemophilia

Important Safety Information

WARNING: THROMBOSIS

  • Serious arterial and venous thrombotic events following administration of NovoSeven® RT have been reported
  • Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven® RT
  • Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis

Warnings and Precautions

  • Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance
  • Patients with congenital hemophilia receiving concomitant treatment with aPCCs (activated prothrombin complex concentrates), older patients particularly with acquired hemophilia and receiving other hemostatic agents, and patients with a history of cardiac and vascular disease may have an increased risk of developing thrombotic events
  • Hypersensitivity reactions, including anaphylaxis, can occur with NovoSeven® RT. Patients with a known hypersensitivity to mouse, hamster, or bovine proteins may be at a higher risk of hypersensitivity reactions. Discontinue infusion and administer appropriate treatment when hypersensitivity reactions occur
  • Factor VII deficient patients should be monitored for prothrombin time (PT) and factor VII coagulant activity (FVII:C). If FVII:C fails to reach the expected level, or PT is not corrected, or bleeding is not controlled after treatment with the recommended doses, antibody formation may be suspected and analysis for antibodies should be performed
  • Laboratory coagulation parameters (PT/INR, aPTT, FVII:C) have shown no direct correlation to achieving hemostasis

Adverse Reactions

  • The most common and serious adverse reactions in clinical trials are thrombotic events. Thrombotic adverse reactions following the administration of NovoSeven® RT in clinical trials occurred in 4% of patients with acquired hemophilia and 0.2% of bleeding episodes in patients with congenital hemophilia

Drug Interactions

  • Thrombosis may occur if NovoSeven® RT is administered concomitantly with Coagulation Factor XIII

Please click here for NovoSeven® RT Prescribing Information, including Boxed Warning.

References
  1. Centers for Disease Control and Prevention. Hemophilia. https://www.cdc.gov/ncbddd/hemophilia/inhibitors.html. September 6, 2018. Accessed February 4, 2021.
  2. National Hemophilia Foundation. MASAC recommendations concerning products licensed for the treatment of hemophilia and other bleeding disorders, #263. New York, NY: National Hemophilia Foundation; 2020.
  3. National Hemophilia Foundation. Guidelines for emergency department management of individuals with hemophilia and other bleeding disorders, #257. New York, NY: National Hemophilia Foundation; 2019.
  4. Riley L, Womack M, Zappa S. Emergency Room Care. In Nurses' guide to bleeding disorders. New York, NY: National Hemophilia Foundation; 2012.
  5. Berntorp E, Shapiro A, Astermark J, et al. Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference. Haemophilia. 2006;12(suppl 6):1-7.
  6. DiMichele DM. Inhibitors in Hemophilia: A Primer. 4th ed. Montréal, Québec, Canada: World Federation of Hemophilia; 2008:1-9.
  7. National Hemophilia Foundation. Recommendation on the use and management of emicizumab-kxwh (Hemlibra®) for hemophilia A with and without inhibitors, #258. New York, NY: National Hemophilia Foundation; 2020.
  8. Center for Disease Control and Prevention. Hemophilia Treatment Center (HTC) Directory. https://www2a.cdc.gov/ncbddd/htcweb/Dir_Report/Dir_Search.asp. Accessed September 18, 2019.
  9. NovoSeven RT [package insert]. Plainsboro, NJ: Novo Nordisk Inc; 2020.
  10. Lentz SR, Ehrenforth S, Abdul Karim F, et al; adept™2 investigators. Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa. J Thromb Haemost. 2014;12(8):1244-1253.
Rare Bleeding Disorders
Other Therapy Areas
Explore diabetes
Explore obesity
Explore growth-related disorders
Explore rare bleeding disorders
Explore rare renal disorders
Explore hormone replacement therapy
  • Rare Bleeding Disorders Home
  • Product Information
    Products
    • Our Treatments
      How to Order
      Trial Prescriptions
      Recombinant Manufacturing
    Professional Resources
    • Product Resources Library
      Contact Your Representative
  • Professional Education
    Disease Education
    • Clinical Education Library
      Congenital Hemophilia with Inhibitors
      Breakthrough Bleeds
      Acquired Hemophilia
      Glanzmann's Thrombasthenia
      Interactive Joint Bleed Model
    Treatment Guidelines
    • MASAC Guidelines
      WFH Guidelines
    Additional Resources
    • Organizations & Conferences
  • Patient Support
    Product Education
    • Product Education Materials
    Disease Education
    • Disease Education Resources
    Access & Affordability
    • Prescription Savings & Insurance Support
      ICD-10 Codes for Rare Bleeding Disorders

NovoSeven® is a registered trademark of Novo Nordisk Health Care AG.
novoMEDLINK™ is a trademark of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
All other trademarks, registered or unregistered, are the property of their respective owners.

Terms of Use | Privacy Notice | Consumer Health Privacy Notice | Cookie Notice | Privacy Request | Contact Us |
novonordisk-us.com    
© 2023 Novo Nordisk All rights reserved. US23NSVN00057 October 2023

Quick links

Trial prescription programs

Patient access and affordability options

MASAC treatment guidelines

Patient educational materials